РОЛЬ СИСТЕМНОГО И ЛОКАЛЬНОГО ВОСПАЛЕНИЯ В РАЗВИТИИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ
Аннотация
В статье представлен анализ современных данных о роли системного и локального воспаления в развитии диабетической нефропатии. Описаны различные аспекты влияния на почки провоспалительных цитокинов: фактора некроза опухолей-α, интерлейкина-1, интерлейкина-6, интерлейкина-18. Рассмотрены основные направления патогенетической терапии. Сделаны выводы о необходимости дальнейшего изучения воспалительных механизмов поражения почек при сахарном диабете, а также клинического и прогностического значения маркеров воспаления при диабетической нефропатии
Об авторах
И. Ю. ПЧЕЛИН
Санкт-Петербургский государственный университет
Россия
Кафедра факультетской терапии медицинского факультета
Россия
Кафедра факультетской терапии медицинского факультета
А. Н. ШИШКИН
Санкт-Петербургский государственный университет
Россия
Кафедра факультетской терапии медицинского факультета
Россия
Кафедра факультетской терапии медицинского факультета
О. А. ЛАПТЕВА
Санкт-Петербургский государственный университет
Россия
Кафедра факультетской терапии медицинского факультета
Россия
Кафедра факультетской терапии медицинского факультета
Список литературы
1. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет 2011; (1): 81-88
2. Jerums G., Premaratne E., Panagiotopoulus S. et al. New and old markers of progression of diabetic nephropathy. Diab Res Clin Pract 2008; 82: 30-37
3. Nosadini R., Tonolo G. Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy. J. Am Soc Nephrol 2004; 15 [Suppl 1]: S1-S5
4. Alaveras A.E.G., Thomas S.M., Sagriotis A. et al. Promoters of progression of diabetic nephropathy: The relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12 [Suppl 2]: 71-74
5. Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure independent effect. Circulation 2002; 106: 672-678
6. Karalliedde J., Gnudi L. ACCORD and ADVANCE: A tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 2008; 23: 1796-1798
7. Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792
8. Kelly K.J., Domingues J.H. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J. Nephrol 2010; 32: 469-475
9. Kaul K., Hodgkinson A., Tarr J.M. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diab Rev 2010; 6: 294-303
10. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin Endocrinol Metab 2009; 94: 3171-3182
11. Segerer S., Nelson P.J., Schlondorff D. Chemokines, Chemokine Receptors, and Renal Disease: From Basic Science to Pathophysiological and Therapeutic Studies. J. Am Soc Nephrol 2000; 11: 152-176
12. Fornoni A., Ijaz A., Tejada T. et al. Role of Inflammation in Diabetic Nephropathy. Curr Diab Rev 2008; 4: 10-17
13. Navarro-Gonzalez J.F., Mora-Fernandez C. The Role of Inflammatory Cytokines in Diabetic Nephropathy. J. Am Soc Nephrol 2008; 19: 433-442
14. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of TNF-α in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17: 441-450
15. Ray A., Huisman M.V., Tamsma J.T. et al. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. Eur J. Int Med 2009; 20: 253-260
16. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
17. Dandona P., Chaudhuri A. Anti-inflammatory and antiatherogenic effects of Insulin. Insulin 2006; 1 [Suppl 1]: S11-S17
18. Welsh G.I., Hale L.J., Eremina V. et al. Insulin Signaling to the Glomerular Podocyte Is Critical for Normal Kidney Function. Cell Metab 2010; 12: 329-340
19. Hyvonen M.E., Saurus P., Wasik A. et al. Lipid phosphotase SHIP2 downregulates insulin signaling in podocytes. Moll Cell Endorinol 2010; 328: 70-79
20. Siragy H.M., Awad A., Abadir P. et. al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003; 144: 2229-2233
21. Siragy H.M., Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 2008; 93: 817-824
22. Theilig F. Spread of glomerular to tubulointerstitial disease with a focus on proteinuria. Ann Anat 2010; 192: 125-132
23. Шишкин А.Н. Факторы роста и гломерулосклероз при диабетической нефропатии. Нефрология 2005; 9(4): 104107
24. Li J.H., Huang X.R., Zhu H.-J. et al. Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-2019
25. Nicholas S.B., Liu J., Kim J. et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010; 77: 588-600
26. Yevdokimova N., Wahab N.A., Mason R.M. Thrombospondin-1 Is the Key Activator of TGF-ß1 in Human Mesangial Cells Exposed to High Glucose. J. Am Soc Nephrol 2001; 12: 703-712
27. Navarro-Gonzalez J.F., Mora-Fernandez C., De Fuentes M.M. et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
28. Moriwaki Y., Yamamoto T., Shibutani Y. et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism 2003; 52: 605-608
29. Zozulinska D., Wierusz-Wysocka B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract 2006; 74 [Suppl 1]: S12-S16
30. Wisse B.E. The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity. J. Am Soc Nephrol 2004; 15: 2792-2800
31. Navarro-Gonzalez J.F., Mora C., Muros M. et al. Urinary tumor necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006; 21: 34283434
32. Navarro-Gonzalez J.F., Mora C., Macia M. et al. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J. Kidney Dis 2003; 42 [Suppl 2]: 53-61
33. Dalla Vestra M., Mussap M., Gallina P. et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am Soc Nephrol 2005; 16 [Suppl 1]: S78-S82
34. Nakamura A., Shikata K., Hiramatsu M. et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895
35. Aso Y., Yosida N., Okumura K. et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004; 348: 139-145
36. Jacobsen P., Tarnow L., Carstensen B. et al. Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy. J. Am Soc Nephrol 2003; 14: 2843-2850
37. Lind L. Circulating markers of inflammation and Atherosclerosis. Atherosclerosis 2003; 169: 203-214
38. Raj D.S.C. Role of Interleukin-6 in the Anemia of Chronic Disease. Semin Arthritis Rheum 2009; 38: 382-388
39. Lankhorst C.E., Wish J.B. Anemia in renal disease: Diagnosis and management. Blood Rev 2010; 24: 39-47
40. Buck I., Morceau F., Grigorakaki C. et al. Linking anemia to inflammation and cancer: The crucial role of TNF-α. Biochem Pharmacol 2009; 77: 1572-1579
41. Пчелин И.Ю., Шишкин А.Н. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн. С.-Петерб. ун-та. Сер. 11 2010; (2): 73-80
42. Silverberg D., Wexler D. Anemia, the fifth major cardiovascular risk factor. Transfus Med Hemotherapy 2004; 31: 175-179
43. Keane W.F., Brenner B.M., De Zeeuw D. et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003; 63: 1499-1507
44. Garcia C., Feve B., Ferre P. et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes Metab 2010; 36: 327-338
45. Navarro-Gonzalez J.F., Jarque A., Muros M. et al. Tumor necrosis factor-α as a target for diabetic nephropathy. Cytokine Growth Factor Rev 2009; 20: 165-173
46. Raval G., Mehta P. TNF-α inhibitors: Are they carcinogenic? Drug Health Patient Saf 2010; 2: 241-247
47. Leyva-Jimenez R., Rodrigues-Orozco.AR., Ortega-Pierres L.E. et al. Effect of pentoxifylline on the evolution of diabetic nephropathy. Med Clin 2009; 132: 772-778
48. McCormick B.B., Sydor A., Akbari A. et al. The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Diasease: A Meta-analysis. а 2008; 52: 454-463
49. Navarro-Gonzalez J.F., Milena F.G., Mora C. et al. Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005; 68 [Suppl 99]: S98-S102
50. Navarro-Gonzalez J.F., Mora C., Muros M. et al. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am Soc Nephrol 2005; 16: 21192126
51. Manning P.G., Sutherland W.H.F., Walker R.J. et al. The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res Clin Pract 2008; 81: 209-215
52. Zheng M., Ye S., Zhai Z. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal monocyte chemoattractant protein-1 expression. J. Diabetes Complications 2009; 23: 124-129
53. Sarafidis P.A., Stafylas P.C., Georgianos P.I. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis. Am J. Kidney Dis 2010; 55: 835-847
54. Kostapanos M.S., Liberopoulos E.N., Elisaf M.S. Statin pleiotropy against renal injury. J. Cardiometab Syndr 2009; 4: 4-9
55. Campese V.M., Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71: 1215-1222
56. Balakumar P., Arora M.K., Ganti S.S. et al. Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol Res 2009; 60: 24-32
57. Danis R.P., Sheetz M.J. Ruboxistaurin: PKC-β inhibition for complications of diabetes. Expert Opin Pharmacother 2009; 10: 2913-2925
Для цитирования:
ПЧЕЛИН И.Ю., ШИШКИН А.Н., ЛАПТЕВА О.А. РОЛЬ СИСТЕМНОГО И ЛОКАЛЬНОГО ВОСПАЛЕНИЯ В РАЗВИТИИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ. Нефрология. 2011;15(4):21-26. https://doi.org/10.24884/1561-6274-2011-15-4-21-26
For citation:
PCHELIN I.Yu., SHISHKIN A.N., LAPTEVA O.A. THE ROLE OF SYSTEMIC AND LOCAL INFLAMMATION IN DIABETIC NEPHROPATHY. Nephrology (Saint-Petersburg). 2011;15(4):21-26. (In Russ.) https://doi.org/10.24884/1561-6274-2011-15-4-21-26
Просмотров: 173
Послать статью по эл. почте 